USP Article: Supporting the Detection of Asbestos in Pharmaceutical Talc
Recommendation

2/3 March 2027
Testing and Sampling of Incoming Active Pharmaceutical Ingredients (APIs) and Excipients
The USP has published an article on the implementation of current requirements for asbestos testing in pharmaceutical talc. The article provides an overview for manufacturers, suppliers and contract testing laboratories. It also includes numerous links to further information on the relevant topics.
The article covers:
- the revised USP Talc monograph, which became official on 1 June 2026;
- USP Chapters <901> Detection of Asbestos in Pharmaceutical Talc and <1901> Theory and Practice of Asbestos Detection in Pharmaceutical Talc;
- the implementation of the new requirements by manufacturers, suppliers and contract laboratories.
The article is available on the USP website.
Webinar: "Talc in Pharma"
In response to these developments, ECA has developed a Webinar on Monday, 21 September 2026 from 14:00–16:00 CEST.During the Webinar, Dr Lance Smallshaw (UCB Biopharma SRL, Belgium), who is also a Board Member of the ECA Analytical Quality Control Group, will cover the following topics:
- Introduction to talc in pharmaceuticals
- ECHA classification and scientific basis
- USP monograph and analytical requirements
- FDA enforcement and compliance implications
A Q&A session will follow the presentation, giving participants the opportunity to ask questions.
Related GMP News
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
30.09.2026The Relationship between the BP and the Ph. Eur.
30.09.2026New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
30.09.2026EMA publishes final ICH M13B Guideline and Q&A on Bioequivalence


